Mammographic Criteria for Determining the Diagnostic Accuracy of Microcalcifications in the Detection of Malignant Breast Lesions

Qurat Hadi 1, Imrana Masroor 2, Zainab Hussain 2

1. Radiology, Dow Institute of Radiology (OJHA Campus), Dow University of Health Sciences, Karachi, PAK
2. Radiology, Aga Khan University Hospital, Karachi, PAK

Corresponding author: Zainab Hussain, zainab.hussain@aku.edu

Abstract

Background
Breast cancer is a progressive disease, with conditions secondary to primary breast cancer being among the more common causes of malignancy-related deaths in women. Early diagnosis can halt disease progression and significantly improve patient’s survival. Microcalcifications detected on mammograms may be an indicator of breast cancer. This study assessed the diagnostic accuracy of microcalcifications seen on mammograms for the detection of malignant breast disease when compared with histopathology.

Materials and methods
This study enrolled 144 women referred to the Radiology Department of Aga Khan University Hospital in Karachi, Pakistan, for mammograms and who were found to have suspicious microcalcifications, for which they underwent subsequent biopsy with histopathology over one year. The accuracy of microcalcifications, along with their sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV), were assessed relative to histopathology results.

Results
Compared with histopathology results, microcalcifications had a sensitivity of 88%, and specificity of 62.8%, a PPV of 55.7%, and an NPV of 90.8%. The overall accuracy of microcalcifications was 71.5%.

Conclusions
The presence of microcalcifications on mammograms may predict breast malignancy. Studies with larger numbers of patients are required to determine whether microcalcifications have higher specificity and PPV relative to breast histopathology.

Introduction
Conditions secondary to primary breast cancer are among the most common causes of malignancy-related deaths in women [1]. Worldwide, 21% of patients newly diagnosed with cancer are found to have conditions secondary to breast cancer, with average lifetime risks of about 6.2% in developed countries and 2.2% in developing countries [2]. A study in the Netherlands estimated that the prevalence of breast cancer is 6.3%, consistent with the results of studies reporting that more than 50% of breast cancer patients worldwide live in developing countries, where resources to fight this disease are insufficient [3].

The burden of breast cancer disease is higher in Pakistan than in other Asian countries [4-5]. The Karachi Cancer Registry has reported that breast cancer is the most frequent cancer (34.6%) among women in Pakistan, a country with one of the highest rates of breast cancer incidence worldwide, with approximately one in every nine women having a lifetime risk of breast cancer [4]. Moreover, breast cancer tends to present at a more advanced stage in Pakistani women than in women in western countries [5].

Studies in western countries have shown that screening mammography reduces breast cancer mortality by 40% to 45% [6]. Mammography is therefore recommended for the early detection of breast cancer, with a significant percentage of women aged more than 40 years in the United States enrolling in these screening programs [7].

Despite the progressive nature of the disease, its progress can be halted by early diagnosis and timely management [8]. High-resolution mammography with a low dose film screen is the standard technique for
early identification of breast cancers, with about 25% to 43% of non-palpable cancers identified on mammography by the presence of calcifications [1]. The presence of microcalcifications on mammography has resulted in the detection of 62% to 98% of ductal carcinomas in situ (DCIS) [9]. Mammography was found to have a sensitivity of 95.2% and a specificity of 41.4% in detecting microcalcifications [10]. The American College of Radiology (ACR) standardized reporting system, called the Breast Imaging Reporting and Data System (BI-RADS) [11] has classified microcalcifications associated with breast cancer as pleomorphic or heterogeneous and as fine and/or branching (casting) calcifications.

A study in Japan assessing the positive predictive value (PPV) of different categories of microcalcifications according to BI-RADS found that 92% of linear and 67% of pleomorphic microcalcifications were malignant [12], and an evaluation of the PPV according to the BI-RADS classification reported that interobserver agreement was fair [13]. Additional studies are needed to improve the accuracy and standardization of mammographic findings of microcalcifications. To our knowledge, no such study has been performed to date in Pakistan. The present study, therefore, evaluated the associations between different types of microcalcifications and breast malignancy.

**Materials And Methods**

This prospective, cross-sectional analytical study involved patients referred to the Department of Radiology of Aga Khan University Hospital in Karachi, Pakistan. The sample size was estimated based on World Health Organization software determinations of sample size in health studies. Microcalcifications have been reported to have a sensitivity of 95.2% and a specificity of 41.4% in detecting breast cancers, and 34.6% of Pakistani women with cancer have been reported to have breast cancer. Thus, based on a 95% confidence interval and a margin of error of 10%, 144 patients are required to evaluate the diagnostic accuracy of microcalcifications on mammography in identifying malignant breast lesions. Non-probability, purposive sampling was used.

The present study enrolled all women referred to the Radiology Department of Aga Khan University Hospital for mammography, who were found to have suspicious microcalcifications (pleomorphic and fine branching) and underwent subsequent biopsy with histopathologic examination. Patients with a previous history of breast cancer were excluded, as were patients who underwent evaluation at another hospital with non-availability of histopathology results.

Written informed consent was obtained from all included patients. Mammography was performed on a MAMMOMAT NOVA 3000 Siemens (Amber Diagnostics, Inc., Orlando, FL) at 26--30 kVp, with images acquired in mediolateral, oblique, and craniocaudal projections. The mammograms were analyzed by an experienced consultant radiologist with at least five years of experience, and the histopathology results were analyzed by an experienced pathologist with at least five years of experience. True positives were defined as mammograms showing microcalcifications associated with malignancy (pleomorphic and fine branching type), with breast cancer subsequently confirmed on histopathology examinations. True negatives were defined as mammograms showing benign-appearing microcalcifications, with non-malignancy subsequently confirmed by histopathology.

Mammogram findings were compared with histopathology results, regarded as the gold standard. All statistical analyses were performed using SPSS for Windows, Version 16.0 (SPSS Inc., Chicago). The sensitivity, specificity, PPV, negative predictive value (NPV), and diagnostic accuracy of microcalcifications in the detection of breast cancer were calculated relative to histopathology. Age was reported as mean and standard deviation (SD), whereas pleomorphic, fine branching, and non-malignant microcalcifications; family history of breast cancer, nulliparity and use of hormone replacement therapy (HRT) were reported as frequencies and percentages. Patients were stratified by age, family history of breast malignancy, use of HRT and nulliparity, and the effects of these variables on outcomes were calculated.

**Results**

The present study enrolled all women who were referred to our department for suspicious breast microcalcifications. Histopathology showed that 50 (35%) of these patients had biopsy-proven breast carcinoma. Mammography correctly identified malignancy in 44 (88%) of these 50 patients, but incorrectly identified benign lesions in six (12%) patients (Table 1). Histopathologic examination showed no evidence of malignancy in the remaining 94 (65%) patients; however, mammography incorrectly identified 35 (37.2%) of these patients as suspicious for malignancy. The accuracy of mammography in evaluating microcalcifications was 71.5%.
|                        |        |
|------------------------|--------|
| Total patients         | 144    |
| True positive          | 44     |
| True negative          | 59     |
| False positive         | 35     |
| False negative         | 6      |
| Sensitivity            | 88%    |
| Specificity            | 62.8%  |
| Accuracy               | 71.5%  |
| NPV                    | 90.8%  |
| PPV                    | 55.7%  |

**TABLE 1: Statistical evaluation of the ability of microcalcifications to predict breast cancer**

Abbreviations: NPV, negative predictive value; PPV, positive predictive value

Pleomorphic and fine branching microcalcifications (malignant) were present in 73 (50.7%), and six (4.2%) patients, respectively. Other (benign) microcalcifications were observed in 65 (45.1%) patients (Table 2).

| Age, year, mean ± SD | N     | Percent   |
|----------------------|-------|-----------|
| 144                  | 55.31 ± 9.79 |

| Positive family history | 51 | 35.4 |
| Nulliparity            | 15 | 10.4 |
| Use of HRT             | 19 | 13.2 |
| Pleomorphic microcalcifications | 73 | 50.7 |
| Fine branching microcalcifications | 6 | 4.2 |
| Other microcalcifications | 65 | 45.1 |
| Histopathologic evidence of breast cancer | 50 | 35 |

**TABLE 2: Demographic and clinical characteristics of patients included in this study**

Abbreviations: HRT, hormone replacement therapy; SD, standard deviation.

The enrolled patients ranged in age from 31 to 82 years, with a mean ± SD age of 55.31 ± 9.79 years. The largest age group consisted of patients aged 51-60 years, accounting for 56 (38.9%) of the 144 patients. The age group with the highest percentage of patients having breast carcinoma was aged 31-40 years (5/9, 56%).

Of the 144 patients, 51 (35.4%) had a family history of breast cancer, 15 (10.4%) were nulliparous, and 19 (13.2%) had taken HRT.

**Discussion**

Breast cancer is one of the most common causes of cancer deaths among women [1]. Early recognition and effective treatment of women diagnosed with breast cancer are keys to reducing mortality rates [8]. Although breast self-examination and regular clinical examination have enhanced early detection of breast cancer, imaging is of paramount importance due to the occult nature of this disease.

Mammography has been found to be an effective screening test for the timely identification of breast cancer. Owing to the presence of microcalcifications, mammography has been found to detect 25%-43% of non-
palpable cancers [1], including 62%-98% of DCISs [9]. The association between microcalcifications and breast malignancy is not specific; however, microcalcifications are also present in women with benign breast diseases, including fibrocystic changes. Many radiological criteria have been proposed to differentiate malignant from benign calcifications [13], including the ACR formulated BI-RADS, most recently revised in 2013 [11].

The present study found that the overall diagnostic accuracy of mammography in detecting microcalcifications associated with breast cancer was 71.5%, with a sensitivity of 88%, a specificity of 62.8%, a PPV of 55.7%, and an NPV of 90.8%. These findings were in agreement with those of a previous study, which reported that mammography had a sensitivity of 95.2% and a specificity of 41.4% in detecting malignant microcalcifications [10].

Of the 144 patients included in this study, 73 (50.7%) had pleomorphic calcifications on mammography, with 39 of the latter (53.4%) being histopathologically positive for breast cancer. Thus, the diagnostic accuracy of mammography in detecting breast carcinoma in patients with pleomorphic calcifications was calculated to be 71.0%. In contrast, only six patients (4.2%) had fine branching microcalcifications on mammography, with five (83.3%) of these patients being histopathologically diagnosed with breast malignancy. The diagnostic accuracy of mammography in detecting breast carcinoma in patients with fine branching microcalcifications was, therefore, 91.5% (Figure 1A, 1B).

In comparison, a study from Japan found that pleomorphic microcalcifications and fine branching microcalcifications on mammography had PPVs of 67% and 92%, respectively, for detection of malignancy [12]. Another study found that two readers had PPVs of 17% and 25%, respectively, for category 4, and 68% and 44%, respectively, for Category 5 breast microcalcifications according to the BI-RADS classification [13]. Similarly, fine pleomorphic lesions on mammography had a PPV for breast malignancy of 28% [14], and linear calcifications had a PPV of 81% [15]. The results of the present study are consistent with these previous findings.

Mammography detected other (benign) microcalcifications in 65 (45.1%) of our 144 patients, with 59 (90.8%) diagnosed as benign and six (9.2%) diagnosed as malignant on histopathology (Figure 2A, 2B). The patients with false-negative results showed punctuate/amorphous calcifications (Figure 3A, 3B). As in our study, the BI-RADS classifies punctate calcifications as benign. One study found that, of 141 lesions, three DCISs had punctate, coarse, and coarsening microcalcifications, respectively, on mammography [16]. The higher rate of false negatives in our study may have been due to our classification of amorphous and coarse heterogeneous calcifications as benign. In contrast, the BI-RADS categorizes these lesions as intermediate calcifications, with studies showed that these microcalcifications are associated with an increased risk of malignancy [12,17]. In comparison, amorphous and coarse heterogeneous calcifications were reported to have PPVs of 20% each [14], and 26% of breast carcinomas were found to have amorphous microcalcifications [15].
In our study, microcalcifications in 35 patients, including 34 pleomorphic and one fine linear branching microcalcifications, were interpreted on mammography as positive results but found to be negative on histopathology (Figure 4A, 4B). Histopathologic examination of biopsies of these 35 lesions showed that 25 of these patients had foci consistent with fibrocystic changes/fibroadenomatosis/sclerosing adenosis, eight had duct ectasia/cysts, seven had columnar cell changes with nuclear atypia in one patient, six had apocrine metaplasia, five had benign breast tissue, two had papillomas, and one each had a fibroadenoma and fat necrosis. Some of these lesions can present as pleomorphic calcifications [18-23].
FIGURE 4: Craniocaudal (A) and mediolateral oblique (B) views in a patient showing early pleomorphism in the upper outer quadrant of left breast, however, histopathology revealed benign breast tissue with fibroadenomatoid change and stromal calcifications. (False Positive)

Fibrocystic breast disease is a common condition among premenopausal women, resulting from different combinations of basic histologic lesions, including epithelial proliferations, lactiferous cysts, stromal fibrosis, sclerosing adenosis, and apocrine metaplasia [18]. Fibrocystic breast disease may be associated with other benign breast disorders, such as atypical lobular hyperplasia, and may manifest on mammography as clusters of microcalcifications, simulating low-grade DCIS [19].

Sclerosing adenosis, a form of fibrocystic change, frequently mimics breast carcinoma. Mammographic findings of sclerosing adenosis include microcalcifications; circumscribed, ill-defined, and spiculated masses; focal asymmetry; and focal architectural distortion [20]. Benign papillomas are another common type of breast lesion that can mimic carcinoma. Mammographically, benign papillomas present as single or multiple circumscribed or irregular masses, with or without microcalcifications [21]. Occasionally, fibroadenomas may contain small punctate, dystrophic, or pleomorphic calcifications [22]. Fat necrosis can present as various types of mammographic abnormalities, including clustered pleomorphic microcalcifications [23].

The mean age of the patients in our study was 55.51 years, with patients ranging in age from 31 to 82 years, and 56 patients aged 51 to 60 years. Patients with suspicious microcalcifications later confirmed histopathologically as being breast cancer ranging in age from 31 to 74 years. Of the various subgroups by age, patients aged 31 to 40 years contained the highest percentage with breast carcinoma (5/9, 56%), a finding that may be due to improved detection of breast carcinoma in younger women. A study assessing the survival of patients in Lahore, Pakistan, with locally advanced breast cancer found that the median age of breast cancer patients was 45 years, with the majority being pre-menopausal and having the receptor-negative disease [24].

Family history has been reported to be a significant risk factor for breast cancer development, especially in younger women. Of the 50 women with histologically proven breast cancer in our study, five (10%) had a positive family history. In comparison, a population-based survey reported that positive family history for various types of cancer had a sensitivity of 61.1%, a specificity of 95%, an NPV of 61.3% and a PPV of 95% for the same type of cancer [25].

Nulliparity is a documented risk factor for breast malignancy, particularly when compared with parity in young women. Nulliparous women have a higher risk (20%–40%) of developing post-menopausal breast malignancy than women who had their first child before the age of 25 years [26]. Of the 50 nulliparous women in our study, six (12%) had breast cancer. Primary data from four National Cancer Institute prospective studies found that nulliparous women had a 38% higher risk of breast cancer than women who had their first child before the age of 25 years, with the overall risk of breast cancer being 11% higher among nulliparous than parous women [27].

HRT may also be associated with an increased frequency of breast cancer in postmenopausal women based on evidence from three studies, the Collaborative Reanalysis (CR), the Women’s Health Initiative (WHI), and
Breast mammography is regarded as the best tool for assessing microcalcifications. Thus, other breast imaging tools, such as ultrasound and magnetic resonance imaging, cannot replace mammography in the early detection of breast malignancy [12]. Our results confirm that mammographic determinations of microcalcifications are a sufficiently sensitive and accurate tool for detecting breast cancer. However, multicenter studies including larger numbers of patients are needed to assess the specificity and PPV of this method.

The ACR BI-RADS utilizes many terms to describe the morphology of microcalcifications. Each term is used to rank lesions into categories that can be used to estimate their malignant potential. These categories include benign, intermediate concern, and a higher probability of malignancy [11]. Although the BI-RADS does not classify descriptions of microcalcification distribution into risk grades, these descriptions, especially of linear and segmental patterns, can help in estimating the possibility of malignancy [12,15,17].

The outcomes of this study and their confirmation of previous results suggest that suspicious microcalcifications, including pleomorphic and fine branching calcifications, should be biopsied prior to any operative intervention.

This study had several limitations. First, this study included a relatively small number of patients presenting at a single center; therefore, the results cannot be generalized. Second, this study, unlike previous studies, did not assess the PPVs of morphology and distribution simultaneously. Third, amorphous and coarse heterogeneous calcifications were considered benign rather than intermediate, as in the BI-RADS classification.

**Conclusions**

These findings confirmed that mammographic determination of microcalcifications is an adequately sensitive and accurate tool for the detection of breast cancer. This study also showed that morphological descriptions of microcalcifications and BI-RADS categories are helpful in predicting the risk of malignancy of suspicious microcalcifications. However, multicenter studies with larger numbers of patients are required to further evaluate the specificity and PPV of morphology and distribution simultaneously.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. College of Physicians and Surgeons Pakistan issued approval RAD-2008-175-946. This is part of a post graduate residence research paper. It was approved by the research training and monitoring cell (RTMC) of the College of Physicians and surgeons pakistan and the above mentioned RTMC number is the identity. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that they have no financial relationships at present or prior to the submission of this paper. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the prior three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Yunus M, Ahmed N, Masroor I, Yaqoob I: Mammographic criteria for determining the diagnostic value of microcalcifications in the detection of early breast cancer. J Pak Med Assoc. 2004, 54:24-29.
2. Gilani GM, Kamal S, Akhter AS: A differential study of breast cancer patients in Punjab, Pakistan. J Pak Med Assoc. 2003, 53:478-481.
3. Flobbe K, Bosch AM, Kessels AG, Beets GL, Neelmann PJ, von Meyerfeldt MF, van Engelshoven JM: The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. Arch Intern Med. 2003, 26:1194-1199. 10.1001/archinte.163.10.1194
4. Bhurgri Y: Karachi cancer registry data - implications for the National Cancer Control Program of Pakistan. Asian Pac J Cancer Prev. 2004, 5:77-82.
5. Siddiqui T, Sabi M, Salam A, Khan S: A survival analysis of metastatic breast cancer in Pakistani patients. J Pak Med Assoc. 2001, 51:120-122.
6. The Swedish Organised Service Screening Evaluation Group: Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev. 2006, 15:45-51. 10.1158/1055-9965.EPI-05-0549
7. Weir HK, Thun MJ, Hankey BF, et al.: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003, 3:1276-1299. 10.1093/jnci/dgf040
8. Tabar L, Dean BP: Thirty years of experience with mammography screening: a new approach to the diagnosis and treatment of breast cancer. Breast Cancer Res. 2008, 10:5. 10.1186/bcr2163
9. Shin HJ, Kim HH, Kim SM, Kwon GY, Gong G, Cho OK: Screening-detected and symptomatic ductal carcinoma in situ: differences in the sonographic and pathologic features. AJR Am J Roentgenol. 2008, 190:515-525. 10.2214/AJR.07.2206
10. Fischer U, Baum F, Obenauer S, Luftner-Nagele S, von Heyden D, Vossenrich R, Grabbe E: Comparative study in patients with microcalcifications: full-field digital mammography vs. screen-film mammography. Eur Radiol. 2002, 12:2679-2683.
11. Sickles EA, D’Orsi CJ, Bassett LW, et al.: ACR BI-RADS® Mammography. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. American College of Radiology, Reston, VA, USA; 2013. 5.
12. Uematsu T, Kasami M, Yuen S: Usefulness and limitations of Japan mammography guidelines for the categorization of breast microcalcifications. Breast Cancer. 2008, 15:291-297. 10.1007/s12282-008-0053-4
13. Gulsun M, Demirkazik BF, Ariyurek M: Evaluation of breast microcalcifications according to imaging reporting and data system criterion and Le Gal’s classification. Eur J Radiol. 2002, 47:583-589. 10.1016/S0720-048X(02)00181-X
14. Liberman L, Abramson AF, Squires FB, Glassman JR, Morris EA, Dershaw DD: The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories. AJR Am J Roentgenol. 1998, 171:35-40. 10.2214/ajr.171.1.9648759
15. Bent CK, Bassett LW, D’Orsi CJ, Sayre JW: The positive predictive value of BI-RADS microcalcification descriptors and final assessment categories. AJR Am J Roentgenol. 2010, 194:1578-1583. 10.2214/AJR.09.5425
16. Orel SG, Kay N, Reynolds C, Sullivan DC: BI-RADS categorization as a predictor of malignancy. Radiology. 1999, 211:845-850. 10.1148/radiology.211.3.99jm31845
17. Burschide ES, Ochner J, Fowler K, Fine JP, Salkowski LR, Rubin DL, Sinsey GA: Use of microcalcification descriptors in BI-RADSto stratify risk of malignancy. Radiology. 2002, 226:583-589. 10.1148/radiol.2265012130
18. Ashbeck EL, Rosenberg RD, Staubner PM, Key CR: Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16:467-472. 10.1158/1055-9965.EPI-06-0394
19. Chan HHL, Lam TPW, Yuen JHF, Leong LLY: Conditions that mimic primary breast carcinoma on mammography and sonography. J HK Coll Radiol. 2004, 7:49-55.
20. Günhan-Bilgen I, Memis A, Ustün EE, Ozdemir N, Erhan Y: Sclerosing adenosis: mammographic and ultrasonographic findings with clinical and histopathological correlation. Eur J Radiol. 2002, 44:232-238.
21. Lam WW, Chu WC, Tang AP, Tse G, Ma TK: Role of radiologic features in the management of papillary lesions of the breast. AJR Am J Roentgenol. 2006, 186:1322-1327. 10.2214/AJR.04.1908
22. Goel NB, Knight TE, Pandeyy S, Ridickyy Young M, de Paredesy S, Trivediy A: Fibrous lesions of the breast: imaging-pathologic correlation. Radiographics. 2005, 25:1547-1559. 10.1148/rg.256045183
23. Bilgen IG, Ustun EE, Memis A: Fat necrosis of the breast: clinical, mammographic and sonographic features. Eur J Radiol. 2001, 39:92-99. 10.1016/S0720-048X(00)00303-X
24. Iqbal J, Banoy S, Saeed A, Akram M, Aziz Z: Survival of women with locally advanced breast cancer at a teaching hospital in Lahore. J Pak Med Assoc. 2010, 60:721-725.
25. Mai PL, Gareeou AO, Graubard BI, et al.: Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst. 2011, 11:18:788-797. 10.1093/jnci/djr114
26. Chauhan A, Subba SH, Menezes RG, Shetty BS, Thakur V, Chahara S, Warrier R: Younger women are affected by breast cancer in South India - a hospital-based descriptive study. Asian Pac J Cancer Prev. 2011, 12:709-711.
27. Schonfeld SJ, Pfeiffer RM, Lacey JV, et al.: Hormone-related risk factors and postmenopausal breast cancer among nulliparous versus parous women: an aggregated study. Am J Epidemiol. 2011, 173:509-517. 10.1093/aje/kwq404
28. Shah NR, Wong T: Current breast cancer risks of hormone replacement therapy in postmenopausal women. Expert Opin Pharmacother. 2006, 7:2455-2465. 10.1517/2673965566.7.18.2455

2019 Hadi et al. Cureus 11(10): e5919. DOI 10.7759/cureus.5919